Somewhat similar, both trials rely on the CRISPR/Cas9 gene editing of the human PD1 gene or a multiplex strategy to edit TRAC, TRBC, and PDCD1 genes in autologous T-cells extracted from cancer patients in order to enhance the antitumor effect. The gene discussed is PDCD1; the disease is cancer.